VACCELERATE

VACCELERATE

Ongoing Rapid Test Study MAK5-50+

Warum haben wir Husten und Schnupfen?

In unserer Studie MAK-5-50+ bestimmen wir mittels Schnelltest, welche Viren (Corona, Influenza A und B, Adeno, RSV) Erkältungssymptome bei Personen in ganz Deutschland hervorrufen. Die Tests funktionieren wie Corona-Tests, können aber fünf Viren anzeigen. Die Untersuchung geht über ein Jahr. Die Teilnehmenden bekommen die Tests per Post zugeschickt und melden die Ergebnisse online.

Sie können die Ergebnisse live hier verfolgen. Die Daten werden regelmäßig von uns aktualisiert. Weitere Informationen: https://vaccelerate.eu/mak-5-50/

Stichtaguntersuchung

Die Punktprävalenz (Stichtaguntersuchung) gibt an, wie viele Personen zu einem bestimmten Zeitpunkt von einer Krankheit oder einem Zustand betroffen sind. In diesem Fall gilt sie daher als eine Momentaufnahme der Häufigkeit von verschiedenen Erregern der Erkältungskrankheiten (SARS-CoV-2, Influenza A, Influenza B, ADV und RSV). n = 2.419 (76.5%) der MAK5 50+ Teilnehmenden haben am 15.12.2024 getestet und ihre Ergebnisse gemeldet. ADV ist mit n = 39 nachgewiesenen Infektionen der am häufigsten gemeldete Erreger, gefolgt von SARS-CoV-2 mit n = 37 und Influenza A mit n = 31. 

Why do we have cough and colds?

In our MAK-5-50+ study, we use rapid tests to determine which viruses (COVID-19, Influenza A and B, Adenovirus, RSV) cause cold symptoms in people throughout Germany. The tests work like COVID tests, but can detect five viruses. The study covers the period of one year. Participants receive the tests by post and report the results online.

You can follow the results here. We will update the data regularly. Further information: https://vaccelerate.eu/mak-5-50/

Point Prevalence 

The point prevalence indicates how many people are affected by a disease or condition at a certain point in time. In this case, it is therefore considered a snapshot of the frequency of various pathogens (SARS-CoV-2, influenza A, Influenza B, ADV and RSV). n = 2,419 (76.5%) of MAK5 50+ participants tested and reported their results on 15 December 2024. ADV is the most frequently reported pathogen with n = 39 detected infections, followed by SARS-CoV-2 with n = 37 and Influenza A with n = 31. 

https://vaccelerate.eu/mak-5-50/

 

What is VACCELERATE?

 

VACCELERATE is a pan-European clinical research network established to accelerate vaccine trials and pandemic preparedness. Funded by the European Union under the Horizon 2020 program, the project aimed to streamline and harmonize clinical trial efforts across Europe, facilitating rapid access to trial sites, expert teams, and standardized protocols.

Key aspects of VACCELERATE include:

  • Building a clinical trial network across Europe and associated countries
  • Expediting (vaccine) research by coordinating trials efficiently
  • Engaging the public through initiatives like the Volunteer Registry to increase participation in clinical studies
  • Harmonizing data collection to improve research quality and comparability
  • Providing training and capacity-building for clinical researchers
  • Investigating vaccines in under-researched populations (e.g., children and the elderly)

Although the EU funding for VACCELERATE has ended on 27 January 2025, the established infrastructure and collaborations are expected to continue supporting future (vaccine) research and public health initiatives.

Questions? Remarks? Contact us: info@vaccelerate.eu. 

Social media updates after 27 January 2025 on https://bsky.app/profile/olivercornely.bsky.social and https://www.linkedin.com/in/oliver-a-cornely-7859b747/.

Continued VACCELERATE Infrastructure

VACCELERATE Study Nurse Course

Find out more about this VACCELERATE course providing the needed expertise to conduct a clinical trial

Learn more

Volunteer Registry

> 107.000 Volunteers

We have set up a database in which you can register if you are interested in participating in a clinical study.

Learn more

Clinical Trial Sites

525 Sites

The VACCELERATE Site Network is a platform for experienced clinical trial sites interested in conducting (vaccine) studies. You can register by answering a short questionnaire.

Learn more

Partners

Project updates between February 2021 and January 2025: